{
    "name": "cedazuridine/decitabine",
    "comment": "Rx",
    "other_names": [
        "Inqovi"
    ],
    "classes": [
        "Cytidine Deaminase Inhibitors",
        "Antineoplastics",
        "DNA Methylation Inhibitors"
    ],
    "source": "https://reference.medscape.com/drug/inqovi-cedazuridine-decitabine-4000080",
    "pregnancy": {
        "common": [
            "Based on findings from human data, animal studies, and its mechanism of action, may cause fetal harm when administered to pregnant females",
            "No data available on use in pregnant females",
            "Verify pregnancy status in females of reproductive potential prior to initiation",
            "A single published case report of IV decitabine use throughout the first trimester during pregnancy describes adverse developmental outcomes, including major birth defects (structural abnormalities)"
        ],
        "specific": [
            {
                "type": "Animal data ",
                "description": [
                    "IV administration of decitabine to pregnant mice and rats during organogenesis at doses ~7% of the recommended human dose on a body surface area (mg/m",
                    ") basis caused adverse developmental outcomes, including increased embryofetal mortality, alterations to growth, and structural abnormalities",
                    "Advise pregnant females of the potential risk to a fetus"
                ]
            },
            {
                "type": "Contraception",
                "description": [
                    "Females of reproductive potential: Use effective contraception during treatment and for 6 months after the last dose",
                    "Males with female partners of reproductive potential: Use effective contraception during treatment and for 3 months after the last dose"
                ]
            },
            {
                "type": "Infertility",
                "description": [
                    "Based on findings of decitabine and cedazuridine in animals, male fertility may be impaired",
                    "Reversibility of the effect on fertility is unknown"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "There are no data on the presence of cedazuridine, decitabine, or their metabolites in human milk or on their effects on the breastfed child or milk production",
            "Advise women not to breastfeed during treatment and for at least 2 weeks after the last dose"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "None",
                "May cause fetal harm when administered to pregnant females"
            ],
            "specific": []
        },
        "cautions": {
            "common": [],
            "specific": []
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "azacitidine",
            "description": {
                "common": "cedazuridine will increase the level or effect of azacitidine by  decreasing metabolism. Avoid or Use Alternate Drug. Cedazuridine, a CDA inhibitor, is used with decitabine to increase systemic exposure of decitabine. Use with other drugs metabolized by CDA may increase levels and toxicities of those drugs."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "capecitabine",
            "description": {
                "common": "cedazuridine will increase the level or effect of capecitabine by  decreasing metabolism. Avoid or Use Alternate Drug. Cedazuridine, a CDA inhibitor, is used with decitabine to increase systemic exposure of decitabine. Use with other drugs metabolized by CDA may increase levels and toxicities of those drugs."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cytarabine",
            "description": {
                "common": "cedazuridine will increase the level or effect of cytarabine by  decreasing metabolism. Avoid or Use Alternate Drug. Cedazuridine, a CDA inhibitor, is used with decitabine to increase systemic exposure of decitabine. Use with other drugs metabolized by CDA may increase levels and toxicities of those drugs."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "gemcitabine",
            "description": {
                "common": "cedazuridine will increase the level or effect of gemcitabine by  decreasing metabolism. Avoid or Use Alternate Drug. Cedazuridine, a CDA inhibitor, is used with decitabine to increase systemic exposure of decitabine. Use with other drugs metabolized by CDA may increase levels and toxicities of those drugs."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "palifermin",
            "description": {
                "common": "palifermin increases toxicity of decitabine by Other (see comment). Avoid or Use Alternate Drug. \nComment: Palifermin should not be administered within 24 hrbefore, during infusion of, or within 24 hr after administration of antineoplastic agents. Coadministration of palifermin within 24 hr of chemotherapy resulted in increased severity and duration of oral mucositis."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "acalabrutinib",
            "description": {
                "common": "acalabrutinib, decitabine.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration may increase risk of myelosuppressive effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cholera vaccine",
            "description": {
                "common": "decitabine decreases effects of cholera vaccine by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Immunosuppressive therapies, including irradiation, antimetabolites, alkylating agents, cytotoxic drugs and corticosteroids (used in greater than physiologic doses), may reduce the immune response to cholera vaccine."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dengue vaccine",
            "description": {
                "common": "decitabine decreases effects of dengue vaccine by immunosuppressive effects; risk of infection. Use Caution/Monitor. Immunosuppressive therapies (eg, irradiation, antimetabolites, alkylating agents, cytotoxic drugs, corticosteroids [greater than physiologic doses]) may reduce immune response to dengue vaccine."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dichlorphenamide",
            "description": {
                "common": "dichlorphenamide and decitabine both decrease  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ethotoin",
            "description": {
                "common": "decitabine increases levels of ethotoin by unknown mechanism. Use Caution/Monitor. Based on case reports."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fingolimod",
            "description": {
                "common": "decitabine increases effects of fingolimod by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Concomitant therapy is expected to increase the risk of immunosuppression. Use caution when switching patients from long-acting therapies with immune effects. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "hydroxyurea",
            "description": {
                "common": "decitabine, hydroxyurea. Other (see comment). Use Caution/Monitor. \nComment: Combination may increase risk of myelosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ponesimod",
            "description": {
                "common": "ponesimod and decitabine both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor. Caution if coadministered because of additive immunosuppressive effects during such therapy and in the weeks following administration. When switching from drugs with prolonged immune effects, consider the half-life and mode of action of these drugs to avoid unintended additive immunosuppressive effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "siponimod",
            "description": {
                "common": "siponimod and decitabine both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor. Caution if coadministered because of additive immunosuppressive effects during such therapy and in the weeks following administration. When switching from drugs with prolonged immune effects, consider the half-life and mode of action of these drugs to avoid unintended additive immunosuppressive effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sipuleucel-T",
            "description": {
                "common": "decitabine decreases effects of sipuleucel-T by pharmacodynamic antagonism. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "maitake",
            "description": {
                "common": "maitake increases effects of decitabine by pharmacodynamic synergism. Minor/Significance Unknown. Maitake mushroom has anti-tumor effects (animal/in vitro research)."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "taurine",
            "description": {
                "common": "decitabine decreases levels of taurine by unspecified interaction mechanism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "vitamin A",
            "description": {
                "common": "vitamin A, decitabine. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Antioxidants such as vitamin A enhance the efficacy, and reduce toxicity, of antineoplastic drugs."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "vitamin E",
            "description": {
                "common": "vitamin E, decitabine. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Antioxidants such as vitamin E enhance the efficacy, and reduce toxicity, of antineoplastic drugs."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Leukocytes decreased",
            "percent": "79-87"
        },
        {
            "name": "Platelet count decreased",
            "percent": "79-82"
        },
        {
            "name": "Neutrophil count decreased",
            "percent": "70-73"
        },
        {
            "name": "Hemoglobin decreased",
            "percent": "58-71"
        },
        {
            "name": "Fatigue",
            "percent": "29-55"
        },
        {
            "name": "Glucose increased",
            "percent": "19-54"
        },
        {
            "name": "Albumin decreased",
            "percent": "22-45"
        },
        {
            "name": "Constipation",
            "percent": "20-44"
        },
        {
            "name": "Hemorrhage",
            "percent": "24-43"
        },
        {
            "name": "Alkaline phosphatase increased",
            "percent": "22-42"
        },
        {
            "name": "Myalgia",
            "percent": "9-42"
        },
        {
            "name": "Mucositis",
            "percent": "18-41"
        },
        {
            "name": "Nausea",
            "percent": "25-40"
        },
        {
            "name": "Glucose decreased",
            "percent": "14-40"
        },
        {
            "name": "Arthralgia",
            "percent": "9-40"
        },
        {
            "name": "Dyspnea",
            "percent": "17-38"
        },
        {
            "name": "Diarrhea",
            "percent": "16-37"
        },
        {
            "name": "ALT increased",
            "percent": "13-37"
        },
        {
            "name": "Dizziness",
            "percent": "16-33"
        },
        {
            "name": "Rash",
            "percent": "12-33"
        },
        {
            "name": "Febrile neutropenia",
            "percent": "10-33"
        },
        {
            "name": "Headache",
            "percent": "22-30"
        },
        {
            "name": "Calcium decreased",
            "percent": "16-30"
        },
        {
            "name": "Edema",
            "percent": "10-30"
        },
        {
            "name": "Sodium decreased",
            "percent": "9-30"
        },
        {
            "name": "AST increased",
            "percent": "6-30"
        },
        {
            "name": "Creatinine increased",
            "percent": "7-29"
        },
        {
            "name": "Cough",
            "percent": "7-28"
        },
        {
            "name": "Decreased appetite",
            "percent": "10-24"
        },
        {
            "name": "Upper respiratory tract infection",
            "percent": "6-23"
        },
        {
            "name": "Pneumonia",
            "percent": "7-21"
        },
        {
            "name": "Transaminase increased",
            "percent": "12-21"
        },
        {
            "name": "Abdominal pain",
            "percent": "9-19"
        },
        {
            "name": "Pyrexia",
            "percent": "7-19"
        },
        {
            "name": "Renal impairment",
            "percent": "9-18"
        },
        {
            "name": "Vomiting",
            "percent": "5-15"
        },
        {
            "name": "Sepsis",
            "percent": "6-14"
        },
        {
            "name": "Neuropathy",
            "percent": "4-13"
        },
        {
            "name": "Insomnia",
            "percent": "6-12"
        },
        {
            "name": "Cellulitis",
            "percent": "4-12"
        },
        {
            "name": "Fall",
            "percent": "4-12"
        },
        {
            "name": "Hypotension",
            "percent": "4-11"
        },
        {
            "name": "Arrhythmia",
            "percent": "3-11"
        },
        {
            "name": "Leukocytes decreased",
            "percent": "65-81"
        },
        {
            "name": "Platelet count decreased",
            "percent": "65-76"
        },
        {
            "name": "Neutrophil count decreased",
            "percent": "65-71"
        },
        {
            "name": "Hemoglobin decreased",
            "percent": "41-55"
        },
        {
            "name": "Febrile neutropenia",
            "percent": "10-32"
        },
        {
            "name": "Pneumonia",
            "percent": "7-15"
        },
        {
            "name": "Sepsis",
            "percent": "6-11"
        },
        {
            "name": "Decreased weight",
            "percent": "5-10"
        },
        {
            "name": "Acute febrile neutrophilic dermatosis",
            "percent": "1"
        },
        {
            "name": "Sweet syndrome",
            "percent": "7"
        },
        {
            "name": "Glucose increased",
            "percent": "3-6"
        },
        {
            "name": "Dyspnea",
            "percent": "2-5"
        },
        {
            "name": "Fatigue",
            "percent": "1-5"
        },
        {
            "name": "Cellulitis",
            "percent": "2-4"
        },
        {
            "name": "Sodium decreased",
            "percent": "1-4"
        },
        {
            "name": "Mucositis",
            "percent": "2-3"
        },
        {
            "name": "Myalgia",
            "percent": "2-3"
        },
        {
            "name": "Hemorrhage",
            "percent": "1-3"
        },
        {
            "name": "Arthralgia",
            "percent": "1-3"
        },
        {
            "name": "Transaminases increased",
            "percent": "2"
        },
        {
            "name": "Calcium decreased",
            "percent": "2"
        },
        {
            "name": "Hypotension",
            "percent": "1-2"
        },
        {
            "name": "AST increased",
            "percent": "1-2"
        },
        {
            "name": "ALT increased",
            "percent": "1-2"
        },
        {
            "name": "Albumin decreased",
            "percent": "1-2"
        },
        {
            "name": "Decreased appetite",
            "percent": "1-2"
        },
        {
            "name": "Dizziness",
            "percent": "1"
        },
        {
            "name": "Glucose decreased",
            "percent": "1"
        },
        {
            "name": "Arrhythmia",
            "percent": "1"
        },
        {
            "name": "Fall",
            "percent": "1"
        },
        {
            "name": "Decreased weight",
            "percent": "1"
        },
        {
            "name": "Upper respiratory tract infection",
            "percent": "1"
        },
        {
            "name": "Abdominal pain",
            "percent": "1"
        },
        {
            "name": "Diarrhea",
            "percent": "1"
        },
        {
            "name": "Pyrexia",
            "percent": "0.5-1"
        },
        {
            "name": "Alkaline phosphatase increased",
            "percent": "0.5-1"
        },
        {
            "name": "Rash",
            "percent": "0.5"
        },
        {
            "name": "Tumor lysis syndrome",
            "percent": "0.5"
        },
        {
            "name": "Creatinine increased",
            "percent": "0.5"
        },
        {
            "name": "Insomnia",
            "percent": "0.5"
        },
        {
            "name": "Nausea",
            "percent": "0.5"
        },
        {
            "name": "Edema",
            "percent": null
        }
    ]
}